microRNA-29b mediates Th17/Treg imbalance in chronic obstructive pulmonary disease by targeting IL-22.

IF 0.8 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM
N Zhao, M J Yu, J Xu, H Y Wang, B Liang, L Ding, Y X Zhang, K Du, B L Leng
{"title":"microRNA-29b mediates Th17/Treg imbalance in chronic obstructive pulmonary disease by targeting IL-22.","authors":"N Zhao, M J Yu, J Xu, H Y Wang, B Liang, L Ding, Y X Zhang, K Du, B L Leng","doi":"10.23812/21-15-A","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) represents a chronic inflammatory disorder of the airways induced mainly by cigarette smoking. In the current study, cigarette smoke extract (CSE) was used to develop an in vitro COPD model using human bronchial epithelium (HBE) cells to expound the possible role of microRNA-29b (miR-29b) in COPD. Firstly, miR-29b and interleukin (IL)-22 expression was assessed in serum of 20 healthy non-smokers, 20 healthy smokers and 20 COPD patients as well as CSE-treated HBE cells. Then, miR-29b and IL-22 expression was altered to evaluate their functions in Th17/Treg ratio. miR-29b inhibited Th17/Treg ratio and levels of IL-22; whereas overexpression of IL-22 reversed these trends. Moreover, rescue experiments found that IL-22 neutralized the repressive effects of miR-29b on Th17/Treg ratio and inflammatory response. Finally, we found that miR-29b blocked the JAK/STAT3 pathway in CSE-treated HBE cells. These data highlighted that miR-29bs modulated Th17/Treg imbalance in CSE-induced experimental COPD through inhibition of IL-22-dependent JAK/STAT3 pathway.</p>","PeriodicalId":15084,"journal":{"name":"Journal of biological regulators and homeostatic agents","volume":"35 3","pages":"987-999"},"PeriodicalIF":0.8000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biological regulators and homeostatic agents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23812/21-15-A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 3

Abstract

Chronic obstructive pulmonary disease (COPD) represents a chronic inflammatory disorder of the airways induced mainly by cigarette smoking. In the current study, cigarette smoke extract (CSE) was used to develop an in vitro COPD model using human bronchial epithelium (HBE) cells to expound the possible role of microRNA-29b (miR-29b) in COPD. Firstly, miR-29b and interleukin (IL)-22 expression was assessed in serum of 20 healthy non-smokers, 20 healthy smokers and 20 COPD patients as well as CSE-treated HBE cells. Then, miR-29b and IL-22 expression was altered to evaluate their functions in Th17/Treg ratio. miR-29b inhibited Th17/Treg ratio and levels of IL-22; whereas overexpression of IL-22 reversed these trends. Moreover, rescue experiments found that IL-22 neutralized the repressive effects of miR-29b on Th17/Treg ratio and inflammatory response. Finally, we found that miR-29b blocked the JAK/STAT3 pathway in CSE-treated HBE cells. These data highlighted that miR-29bs modulated Th17/Treg imbalance in CSE-induced experimental COPD through inhibition of IL-22-dependent JAK/STAT3 pathway.

microRNA-29b通过靶向IL-22介导慢性阻塞性肺病中Th17/Treg的失衡。
慢性阻塞性肺病(COPD)是一种主要由吸烟诱发的气道慢性炎症性疾病。本研究利用香烟烟雾提取物(CSE)和人支气管上皮细胞(HBE)建立了一个体外慢性阻塞性肺病模型,以探讨microRNA-29b(miR-29b)在慢性阻塞性肺病中可能发挥的作用。首先,评估了20名健康非吸烟者、20名健康吸烟者和20名慢性阻塞性肺病患者血清中的miR-29b和白细胞介素(IL)-22的表达,以及CSE处理的HBE细胞。miR-29b 可抑制 Th17/Treg 比率和 IL-22 的水平,而 IL-22 的过表达则可逆转这些趋势。此外,拯救实验发现,IL-22 中和了 miR-29b 对 Th17/Treg 比率和炎症反应的抑制作用。最后,我们发现 miR-29b 在 CSE 处理的 HBE 细胞中阻断了 JAK/STAT3 通路。这些数据突出表明,miR-29b通过抑制依赖于IL-22的JAK/STAT3通路,调节了CSE诱导的实验性慢性阻塞性肺病中Th17/Treg的失衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
15.60%
发文量
0
审稿时长
6 months
期刊介绍: Journal of Biological Regulators & Homeostatic Agents (IF 1.397) is a peer-reviewed journal published every 2 months. The journal publishes original papers describing research in the fields of experimental and clinical medicine, molecular biology, biochemistry, regulatory molecules, cellular immunology and pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信